Key points from article :
Mogrify and Astellas Pharma collaborated to develop an in vivo regenerative medicine approach to address sensorineural hearing loss.
Mogrify's direct cellular reprogramming platform will identify novel combinations of transcription factors to generate new cochlear hair cells.
Astellas Gene Therapies will cover the research costs & contribute its expertise in AAV-based genetic medicine and translational capabilities.
Mogrify will exploit its bioinformatic platform, screening and validation process to characterize potential therapeutic factors.
The two companies believe that their collaboration has the potential to lead to a novel and effective treatment for sensorineural hearing loss.
